Press Release

REVOLUTION Medicines Raises $56 Million in Series B Financing

Redwood City, CA – April 24, 2018 – REVOLUTION Medicines, Inc., a drug discovery and development company focused on frontier cancer targets, today announced it has raised $56 million in a Series B financing to support its ongoing R&D programs…

Read more

Publication / Presentation

Publication / Presentation

Press Release

Revolution Medicines Appoints Vincent Miller, M.D. to Board of Directors

Redwood City, CA –October 5, 2017 – REVOLUTION Medicines, Inc., a drug discovery and development company focused on frontier cancer targets, today announced the appointment of Vincent Miller, M.D., to its board of directors. Dr. Miller is a leader…

Read more

Publication / Presentation

Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss

New research revealed an unexpected dependence of some cancer-causing forms of proteins in the RAS-MAP kinase pathway on the normal biochemical actions of SHP2.  These functions can be disrupted by small molecule inhibitors of SHP2 designed by the…

Read more

Press Release

Revolution Medicines Reports Discovery that May Expand Range of Clinically Actionable Cancer Mutations

Redwood City, CA –September 14, 2017 – REVOLUTION Medicines, Inc., a company focused on frontier cancer targets and drug discovery, today published a report entitled “Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling…

Read more

Press Release

Revolution Medicines Appoints Cancer Leader Dr. Stephen Kelsey as President of Research and Development

Redwood City, CA –March 20, 2017 – REVOLUTION Medicines, Inc., a company focused on frontier cancer targets and drug discovery inspired by nature’s lessons, today announced the appointment of Stephen (Steve) Kelsey, M.D., an accomplished…

Read more

Press Release

Revolution Medicines Raises Additional $25 Million in Series A Financing

Redwood City, Calif. – December 20, 2016 – REVOLUTION Medicines, Inc., a company focused on frontier cancer targets and drug discovery inspired by nature’s lessons, today announced that it has raised $25 million in a Series A extension financing.…

Read more